DuraHeart LVAS Clinical Trial Results Are Successful

Armen Hareyan's picture
Advertisement

DuraHeart LVAS Clinical Trial

Terumo Heart had a successful European Launch Symposium at the European Association of Cardio-Thoracic Surgeons (EACTS) meeting in Geneva, Switzerland.

A summary of the European Clinical Trial results for the DuraHeart Left Ventricular Assist System (LVAS) was presented by Dr. Aly El-Banayosy from the Heart Center Nordrhein-Westfalen in Bad Oeynhausen, Germany, followed by the presentation "The Emerging New Era of Mechanical Circulatory Support," by Dr. Eric Rose of Columbia University Medical Center in New York.

Advertisement

The symposium highlighted the DuraHeart device, as well as the BioValsalva Aortic Valved Conduit developed by Vascutek Ltd, a Terumo Company.

A summary of DuraHeart LVAS clinical results to-date (as of September 15, 2007):

* Patients enrolled = 33

* Median age (years) = 57 (29-73)

* Mean support duration (days) = 231

Share this content.

If you liked this article and think it may help your friends, consider sharing or tweeting it to your followers.
Advertisement